Conditions: Vasomotor Symptoms
Keywords: Menopause Hot Flush Hot Flash Desvenlafaxine succinate Sustained Release
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2186
Healthy volunteers: yes

Brief summary:
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.

Detailed description:

Arms:
arm 1: desvenlafaxine succinate (DVS) SR arm 2: Placebo

Interventions: intervention 1: desvenlafaxine succinate (DVS) SR intervention 2: Placebo
Intervention descriptions: intervention 1: Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days. intervention 2: Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.

Protocol document: